Evaluation of retinoblastoma protein expression in endometrial hyperplasia.

UNLABELLED In our study we investigated immunohistochemical expression of retinoblastoma protein (pRb) in physiological endometrium (n = 15), hyperplastic endometrium (n = 61) and post-hormone replacement therapy (HRT) endometrium (n = 24). METHODS We performed an immunohistochemical analysis of pRb expression in 100 specimens of human endometrium. RESULTS The average pRb immunoexpression index score in glandular endometrial cells and stromal endometrial cells were 57,699 and 21,191 respectively. The less intense pRb immunostaining for the glandular cells was displayed in women over 49 years old. The most intense staining effect of glandular cells was observed among patients with physiological endometrium, no older than 49 years of life. There was no statistically significant correlation between the obtained pRb immunoexpression and clinical data of the examined patients. CONCLUSIONS We conclude that immunohistochemistry is not sensitive and specific enough to reveal pRb alterations resulting in endometrium pathologies. Alternatively, pathological rearrangements of endometrium may be independent from the accuracy of the pRb control over restriction point in cell-cycle pathway.

[1]  E. Ioachin.  Immunohistochemical tumour markers in endometrial carcinoma. , 2005, European journal of gynaecological oncology.

[2]  R. Schneider-Stock,et al.  Loss of heterozygosity of the retinoblastoma gene is correlated with the altered pRb expression in human endometrial cancer , 2002, Virchows Archiv.

[3]  A. Giatromanolaki,et al.  Prognostic aspects on endometrial hyperplasia and neoplasia , 2001, Virchows Archiv.

[4]  M. Dietel.  The histological diagnosis of endometrial hyperplasia. Is there a need to simplify? , 2001, Virchows Archiv : an international journal of pathology.

[5]  S. Silverberg.  Problems in the Differential Diagnosis of Endometrial Hyperplasia and Carcinoma , 2000, Modern Pathology.

[6]  R. Schneider-Stock,et al.  RB protein expression in human endometrial carcinomas--an immunohistochemical study. , 2000, Pathology, research and practice.

[7]  M. Masseroli,et al.  A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. , 1999, The American journal of surgical pathology.

[8]  S. Shi,et al.  Loss of heterozygosity of the Rb gene correlates with pRb protein expression and associates with p53 alteration in human esophageal cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  R. Schneider-Stock,et al.  MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas , 1998, Journal of Cancer Research and Clinical Oncology.

[10]  M. Wells,et al.  Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium , 1998, Histopathology.

[11]  Buckley,et al.  Endometrial carcinoma: two or three entities? , 1998 .

[12]  T. Niemann,et al.  Retinoblastoma protein expression in endometrial hyperplasia and carcinoma. , 1997, Gynecologic oncology.

[13]  K. Bilek,et al.  [Endometrial hyperplasias: histology, classification, prognostic significance and therapy]. , 1997, Zentralblatt fur Gynakologie.

[14]  R. Zaino.  Taking another look at endometrial adenocarcinoma. , 1996, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[15]  R. Kratzke,et al.  Wild-type and mutant retinoblastoma protein in paraffin sections. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[16]  P. V. van Diest,et al.  Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer. , 1996, American journal of obstetrics and gynecology.

[17]  X. Graña,et al.  Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). , 1995, Oncogene.

[18]  Hong‐Ji Xu.  Altered Retinoblastoma (RB) Protein Expression in Human Malignancies , 1995 .

[19]  S. Steinberg,et al.  RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. , 1994, Oncogene.

[20]  K. Ishizaki,et al.  Mutation spectrum of the retinoblastoma gene in osteosarcomas. , 1994, Cancer research.

[21]  C. Cordon-Cardo,et al.  Expression of the retinoblastoma protein is regulated in normal human tissues. , 1994, The American journal of pathology.

[22]  M. Inoue,et al.  Alterations of the Rb gene and its association with ki‐ras activation and p53 inactivation in endometrial adenocarcinoma , 1993, Molecular carcinogenesis.

[23]  J. Baak,et al.  Assessment of the risk on endometrial cancer in hyperplasia, by means of morphological and morphometrical features. , 1992, Pathology, research and practice.

[24]  M. Knowles,et al.  Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. , 1991, Oncogene.

[25]  S. Maeda,et al.  Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. , 1991, Cancer research.

[26]  H. Sasano,et al.  An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma , 1990, Cancer.

[27]  W. Lee,et al.  Human retinoblastoma susceptibility gene: cloning, identification, and sequence , 1987, Science.

[28]  Stephen H. Friend,et al.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma , 1986, Nature.